CompletedPhase 3

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

United States464 participantsStarted 2023-03-31

Plain-language summary

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Has a primary diagnosis of schizophrenia.
✓. Is on a stable dose of antipsychotic medication(s).
✓. Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).

Exclusion criteria

✕. Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
✕. Meets DSM-5, for diagnoses not under investigation.
✕. Has participated in a CT-155 clinical study.

What they're measuring

Experiential negative symptoms

Timeframe: Baseline to Week 16

Trial details

NCT IDNCT05838625

SponsorClick Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-20

View on ClinicalTrials.gov More Schizophrenia trials